NEW YORK (GenomeWeb News) – PDI today announced it will buy molecular diagnostics company RedPath Integrated Pathology for more than $23 million in cash and stock.

The purchase helps PDI subsidiary Interpace Diagnostics expand its oncology product portfolio with RedPath's PathfinderTG platform, which includes Pathfinder TG Pancreas, a diagnostic test that helps physicians determine cancer risk in pancreatic cysts. That test generates annual revenues of approximately $10 million, said PDI.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.